296 results on '"Zielinski C"'
Search Results
2. Time to treat the climate and nature crisis as one indivisible global health emergency
3. ESMO Open: from Cancer Horizons to Science for Optimal Cancer Care—a tale stretching over 8 years
4. Time to treat the climate and nature crisis as one indivisible global health emergency
5. Time to treat the climate and nature crisis as one indivisible global health emergency
6. Time to treat the climate and nature crisis as one indivisible global health emergency
7. COP27 climate change conference: Urgent action needed for Africa and the world
8. COP27 Climate Change Conference: urgent action needed for Africa and the world
9. Ventiltriebtechnologien für die Herausforderung Motorrad – Besonderheiten im Vergleich zu Automobilmotoren
10. Introducing pro and con discussions in ESMO Open—Cancer Horizons
11. ESMO Clinical Practice Guidelines: adapting and adopting new approaches for development, implementation and audit
12. Humoral and cellular immune responses and their kinetics vary in dependence of diagnosis and treatment in immunocompromised patients upon COVID-19 mRNA vaccination
13. 229MO Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormone-receptor+/HER2- metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study
14. 415P Comparison of cetuximab every 2 weeks versus standard once-weekly administration for the first-line treatment of RAS wild-type metastatic colorectal cancer among patients with left- and right-sided primary tumor location
15. P-52 Overall survival with cetuximab every 2 weeks vs standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumor location
16. Professor Gouri Shankar Bhattacharyya
17. Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
18. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL
19. 143P Quality of life (QoL) with palbociclib (PAL) plus endocrine therapy (ET) versus (vs) capecitabine (CAP) in luminal metastatic breast cancer (MBC) patients (pts) in the PEARL study
20. Reduced seroprevalence against vaccine preventable diseases (VPDs) in adult patients with cancer: necessity of routine vaccination as part of the therapeutic concept
21. Mammakarzinom
22. Onkologie
23. HER-2/neu in Breast Cancer: A Possible Means of Therapy?
24. Object-Oriented Approach to Programming a Robot System
25. Characterization of MHC class II-restricted T-cell receptors for T-cell therapy of HBV infection
26. Zelluläre Immunitätsparameter bei opiatabhängigen Patienten
27. Brain metastases as first manifestation of advanced cancer: exploratory analysis of 459 patients at a tertiary care center
28. P2.15-03 Availability and Reimbursement of Diagnostic Testing and Novel Anti-Cancer Drugs for NSCLC in CEE: Results of a CECOG Survey
29. P2.12-04 Liposomal Irinotecan vs Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed On/After Platinum-Based Therapy
30. Therapie des metastasierenden Mammakarzinoms
31. Reply to the letter to the editor ‘ESMO-MCBS v1.1: statistical and patient relevant shortcomings’ by Emprechtinger et al.
32. Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients
33. Reply to the letter to the editor ‘Re-aligning the ASCO and ESMO clinical benefit frameworks or modern cancer therapies’
34. Reply to the letter to the editor ‘Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?’ by Del Paggio
35. Regorafenib therapy in metastatic colorectal cancer patients: markers and outcome in an actual clinical setting
36. Correcetions to “A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)”
37. 300 Tonicity signals drive immunoparalysis and anti-inflammatory Th17 cell properties
38. ESMO-Magnitude of Clinical Benefit Scale version 1.1
39. Reply to the letter to the editor ‘Addressing the quality of the ESMO-MCBS’ by Del Paggio
40. Erratum to: Measuring sequences of keystrokes with jsPsych: Reliability of response times and interkeystroke intervals
41. Abstract OT2-01-06: Phase III study of palbociclib (PD-0332991) in combination with endocrine therapy (exemestane or fulvestrant) versus chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with resistance to aromatase inhibitors. “The PEARL study” (GEICAM/2013-02)
42. MONDTI: Molecular characterisation platform for identifying actionable mutations in advanced or metastatic cancers
43. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
44. Reply to the letter to the editor ‘Utilisation of the ESMO-MCBS in practice of HTA’ by Wild et al.
45. Decreased body mass index (BMI) associates with impaired survival from diagnosis of brain metastases in lung cancer patients: analysis of 624 patients
46. Functional role of 4F2hc in pancreatic ductal adenocarcinoma
47. Exploratory analyses of candidate predictive and prognostic tissue biomarkers (BMs) in the open-label randomised phase III TANIA trial of bevacizumab (BEV) in HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
48. Temporal muscle thickness (TMT) is an independent prognostic parameter in patients with newly diagnosed brain metastases (BM) of breast cancer (BC)
49. OS7.4 Outcome of patients presenting with brain metastasis as first manifestation of cancer
50. P04.03 Analysis of the inflammatory tumor microenvironment in meningeal malignancies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.